Skip to main content

Table 5 Mean annual exacerbation rate by asthma therapy

From: Retrospective cohort analysis of healthcare claims in the United States characterising asthma exacerbations in paediatric patients

Age, years

ICSa

ICS/LABA

LTRA

OCS

n

Mean exacerbation rate (SD)

n

Mean exacerbation rate (SD)

n

Mean exacerbation rate (SD)

n

Mean exacerbation rate (SD)

Females

0 -1

2017

1.50 (0.89)

5

1.60 (0.89)

490

1.67 (1.07)

3502

1.42 (0.83)

>1 – 2

2036

1.49 (0.89)

10

2.0 (2.0)

1060

1.59 (1.08)

3709

1.37 (0.74)

>2 – 3

2084

1.46 (0.86)

17

1.35 (0.79)

1440

1.56 (1.0)

3289

1.34 (0.77)

4 – 12

11321

1.36 (0.83)

2034

1.42 (0.93)

12209

1.44 (0.89)

20719

1.29 (0.81)

13 – 17

3693

1.35 (0.93)

3227

1.42 (0.93)

5915

1.45 (1.06)

11070

1.39 (1.01)

Overall 0-17

21151

1.40 (0.86)

5293

1.42 (0.93)

21114

1.46 (0.96)

42289

1.34 (0.86)

Males

0–1

4552

1.60 (1.02)

6

2.0 (0.63)

1232

1.68 (1.09)

6112

1.47 (0.89)

>1–2

3950

1.52 (0.94)

22

1.91 (1.06)

2042

1.65 (1.08)

5803

1.42 (0.81)

>2–3

3630

1.48 (0.93)

40

1.93 (1.46)

2446

1.56 (1.02)

5114

1.40 (0.89)

4–12

19133

1.39 (0.84)

3743

1.42 (0.84)

21698

1.45 (0.92)

32895

1.32 (0.84)

13–17

4208

1.32 (0.85)

3777

1.37 (0.91)

21698

1.45 (0.92)

13397

1.35 (0.92)

Overall 0–17

35473

1.43 (0.89)

7588

1.40 (0.88)

34104

1.45 (1.06)

42289

1.34 (0.86)

  1. aincludes nebulized medications
  2. ICS inhaled corticosteroid, LABA long-acting beta agonist, LTRA leukotriene receptor antagonist, OCS oral corticosteroid